Sign in

NCT06142422Withdrawn

Intermittent Theta Burst Stimulation of the Precuneus

Intermittent Theta Burst Stimulation of the Precuneus for the Treatment of Resistant Schizophrenia

Source: ClinicalTrials.gov · Last updated 4 May 2026

Brief summary (registry, in English)

The purpose of the study is to compare the effectiveness of stimulation of the left precuneus by intermittent Theta Burst Stimulation to placebo stimulation on the severity of schizophrenia symptoms.

Status (registry)
Withdrawn
Study type
Interventional
Enrollment
0 (actual)
First submitted
16 Nov 2023
Start date
Jan 2026
Primary completion date
Jun 2026
Lead sponsor
GCS Ramsay Santé pour l'Enseignement et la Recherche
NCT number
NCT06142422

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Patient with a contraindication to magnetic resonance imaging or intermittent Theta Burst Stimulation (presence of a metallic body, pacemaker, implantable defibrillator or other implantable metallic device, epilepsy, stroke or recent head trauma);
  • Patient in forced care (psychiatric care upon decision of the State representative and psychiatric care at the request of a third party);

Age

  • Pregnant woman or likely to be pregnant (of childbearing age) without effective contraception or breastfeeding;

Other

  • Patient who is not French-speaking or cannot read and write;
  • Patient under guardianship;
  • Patient participating in another clinical trial, or during a period of exclusion from another clinical trial;
  • Patient who is not a beneficiary of a social security system.
  • Patient who, according to the assessment of the investigator, risks not being compliant or diligent in the study procedures.

Who the study is looking for

  • Right-handed patient aged 18 to 40 years inclusive;
  • Patient presenting schizophrenia as defined in the Diagnostic and Statistical Manual-5;
  • Patient under antipsychotic treatment in accordance with the recommendations of the High Authority of Health, at a stable dosage and without modification of psychotherapeutic treatment for at least 4 weeks;
  • Patient on mono or dual antipsychotic therapy.
  • Patient presenting residual symptoms, i.e. absence of remission defined by the criteria of the "Remission criteria of the Schizophrenia Working Group Consensus";
  • Patient having been exposed to at least one type of trauma in childhood and having a score higher than the threshold values of the childhood trauma questionnaire: emotional neglect, physical abuse, emotional abuse, physical neglect, sexual abuse;
  • Patient having signed an informed consent form to participate in the study.

Age in the registry: 18 years to 40 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.